Eric Rutstein, MD
Psychiatry · Boca Raton, FLNPI 1639265333
Payments from drug & device makers
Across 838 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Lundbeck LLC$1K
- Vanda Pharmaceuticals Inc.$923
- plus $9K from 27 others
What the payments were for
- Speaking & faculty fees$4,55019%
- Food & beverage$19,81481%
- Education$1070%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 155 | $7,351 |
| Otsuka America Pharmaceutical, Inc. | 78 | $2,334 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $2,081 |
| Teva Pharmaceuticals USA, Inc. | 72 | $2,005 |
| Lundbeck LLC | 50 | $1,127 |
| Vanda Pharmaceuticals Inc. | 31 | $923 |
| Bausch Health US, LLC | 63 | $905 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $857 |
| Sunovion Pharmaceuticals Inc. | 36 | $828 |
| Almatica Pharma LLC | 40 | $820 |
| Axsome Therapeutics, Inc. | 26 | $804 |
| Alkermes, Inc. | 31 | $802 |
| Neurocrine Biosciences, Inc. | 17 | $493 |
| Johnson & Johnson | 16 | $469 |
| Idorsia Pharmaceuticals US Inc | 8 | $352 |
| Corium, LLC | 16 | $306 |
| Merck | 16 | $272 |
| Eisai Inc. | 12 | $209 |
| Ironshore Pharmaceuticals Inc. | 6 | $202 |
| Avanir Pharmaceuticals, Inc. | 7 | $157 |
| E.r. Squibb & Sons, L.L.C. | 2 | $149 |
| Adlon Therapeutics L.p. | 6 | $126 |
| Acadia Pharmaceuticals Inc | 2 | $123 |
| Noven Pharmaceuticals, Inc. | 1 | $123 |
| Supernus Pharmaceuticals, Inc. | 7 | $122 |
| Jazz Pharmaceuticals Inc. | 6 | $115 |
| Noven Therapeutics, LLC | 5 | $105 |
| Neos Therapeutics, LP | 5 | $98 |
| Neuronetics, Inc. | 2 | $78 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| Shire North American Group Inc | 2 | $36 |
| Alfasigma USA, Inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,471 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 14 | $140,207 |
| IngrezzaValbenazine Tosylate | 13 | $109,123 |
| RexultiBrexpiprazole | 26 | $38,312 |
| CaplytaLumateperone Tosylate | 16 | $26,230 |
| BelsomraSuvorexant | 24 | $10,645 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,290 |
| DayvigoLemborexant | 16 | $8,858 |
| ZoloftSertraline Hcl | 13 | $6,176 |
| Bupropion XlBupropion Hcl | 149 | $4,575 |
| Vilazodone Hcl | 31 | $3,315 |
| PaxilParoxetine Hcl | 12 | $3,295 |
| Duloxetine Hcl | 166 | $3,198 |
| Tranylcypromine Sulfate | 12 | $3,060 |
| Escitalopram Oxalate | 211 | $3,025 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 179 | $2,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,005 | $140,20714 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $493 | $109,12313 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,334 | $38,31226 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,081 | $26,23016 claims |
| MerckBelsomra | $272 | $10,64524 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $857 | $9,29017 claims |
| Eisai Inc.Dayvigo | $209 | $8,85816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Boca Raton
- Theodore TreeseBoca Raton$8.5M
- Richard JacksonBoca Raton$4.1M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.